Steven W. Pipe

10.3k total citations · 3 hit papers
200 papers, 6.7k citations indexed

About

Steven W. Pipe is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Steven W. Pipe has authored 200 papers receiving a total of 6.7k indexed citations (citations by other indexed papers that have themselves been cited), including 160 papers in Hematology, 52 papers in Molecular Biology and 37 papers in Genetics. Recurrent topics in Steven W. Pipe's work include Hemophilia Treatment and Research (145 papers), Blood Coagulation and Thrombosis Mechanisms (76 papers) and Platelet Disorders and Treatments (52 papers). Steven W. Pipe is often cited by papers focused on Hemophilia Treatment and Research (145 papers), Blood Coagulation and Thrombosis Mechanisms (76 papers) and Platelet Disorders and Treatments (52 papers). Steven W. Pipe collaborates with scholars based in United States, Germany and United Kingdom. Steven W. Pipe's co-authors include Randal J. Kaufman, Hongzhi Miao, Johnny Mahlangu, Jyoti Malhotra, Subramaniam Pennathur, Kezhong Zhang, Anna R. Wolfson, Angela C. Weyand, Glenn F. Pierce and Evgueni L. Saenko and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Steven W. Pipe

183 papers receiving 6.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

WFH Guidelines for the Management of Hemophilia, 3rd edition

2020 1.1k citations Alok Srivastava, Elena Santagostino et al. Haemophilia profile →
Antioxidants reduce endoplasmic reticulum stress and improve protein secretion

2008 576 citations Steven W. Pipe, Randal J. Kaufman et al. profile →
Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study

2019 273 citations Steven W. Pipe, Midori Shima et al. The Lancet Haematology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Steven W. Pipe United States	40	4.7k	1.7k	1.0k	945	724	200	6.7k
Hartmut Weiler United States	35	2.2k 0.5×	1.2k 0.7×	430 0.4×	536 0.6×	275 0.4×	121	4.5k
Bruce M. Ewenstein United States	49	4.7k 1.0×	1.3k 0.7×	401 0.4×	1.5k 1.6×	275 0.4×	149	6.9k
Surapol Issaragrisil Thailand	30	2.5k 0.5×	991 0.6×	320 0.3×	1.9k 2.0×	733 1.0×	155	4.5k
Ulrich Jäger Austria	45	2.4k 0.5×	1.8k 1.1×	446 0.4×	1.2k 1.3×	1.7k 2.3×	172	5.7k
Sanford B. Krantz United States	42	3.3k 0.7×	1.5k 0.9×	580 0.6×	2.1k 2.2×	817 1.1×	123	5.8k
Melvin H. Freedman Canada	35	1.8k 0.4×	1.6k 0.9×	1.6k 1.5×	1.2k 1.3×	1.5k 2.0×	140	6.0k
Maria Teresa Voso Italy	39	2.7k 0.6×	2.4k 1.4×	306 0.3×	1.0k 1.1×	1.1k 1.5×	239	5.3k
Andrew M. Yeager United States	30	2.8k 0.6×	996 0.6×	231 0.2×	805 0.9×	899 1.2×	91	4.5k
J W Adamson United States	32	2.7k 0.6×	750 0.4×	318 0.3×	1.4k 1.4×	510 0.7×	70	4.7k
Ming Hou China	39	3.8k 0.8×	622 0.4×	209 0.2×	914 1.0×	360 0.5×	249	5.3k

Countries citing papers authored by Steven W. Pipe

Since Specialization

Citations

This map shows the geographic impact of Steven W. Pipe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven W. Pipe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven W. Pipe more than expected).

Fields of papers citing papers by Steven W. Pipe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven W. Pipe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven W. Pipe. The network helps show where Steven W. Pipe may publish in the future.

Co-authorship network of co-authors of Steven W. Pipe

This figure shows the co-authorship network connecting the top 25 collaborators of Steven W. Pipe. A scholar is included among the top collaborators of Steven W. Pipe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven W. Pipe. Steven W. Pipe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hermans, Cédric, Carmen Unzu, Mark A. Kay, et al.. (2025). Operationalising a Haemophilia Gene Editing Lexicon for Practical Use. Haemophilia. 31(2). 207–213.

Glasner, Margaret E., Steven W. Pipe, & Wolfgang Miesbach. (2025). Gene-based therapies for hemophilia. Research and Practice in Thrombosis and Haemostasis. 9(4). 102870–102870.

Young, Guy, Kaan Kavaklı, Robert Klamroth, et al.. (2025). Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study. Blood. 145(25). 2966–2977. 7 indexed citations

Leavitt, Andrew D., Kaan Kavaklı, Laurent Frenzel, et al.. (2024). Efficacy and Safety of Giroctocogene Fitelparvovec in Adults with Moderately Severe to Severe Hemophilia Α: Primary Analysis Results from the Phase 3 ΑFFINE Gene Therapy Trial. Blood. 144(Supplement 1). 1053–1053. 2 indexed citations

Itzler, Robbin, Tyler W. Buckner, Frank W.G. Leebeek, et al.. (2024). Effect of etranacogene dezaparvovec on quality of life for severe and moderately severe haemophilia B participants: Results from the phase III HOPE‐B trial 2 years after gene therapy. Haemophilia. 30(3). 709–719. 5 indexed citations

Hermans, Cédric, Leonard A. Valentino, Courtney D. Thornburg, et al.. (2024). A novel gene editing lexicon strategy for the haemophilia community: Research plan for development and preliminary results. Haemophilia. 30(6). 1272–1280. 2 indexed citations

Friedman, Kenneth D., Dennis J. Dietzen, Charles Eby, et al.. (2024). Evaluation of an automated von Willebrand factor glycoprotein IbM activity assay compared with 3 alternative von Willebrand factor activity assays. Research and Practice in Thrombosis and Haemostasis. 8(4). 102422–102422. 2 indexed citations

Pipe, Steven W., Barbara A. Konkle, Steve Kitchen, et al.. (2023). A global comparative field study to evaluate the factor VIII activity of efanesoctocog alfa by one‐stage clotting and chromogenic substrate assays at clinical haemostasis laboratories. Haemophilia. 30(1). 214–223. 12 indexed citations

Pierce, Glenn F., Saliou Diop, Amy L. Dunn, et al.. (2022). Achieving access to haemophilia care in low-income and lower-middle-income countries: expanded Humanitarian Aid Program of the World Federation of Hemophilia after 5 years. The Lancet Haematology. 9(9). e689–e697. 38 indexed citations

10.

Srivastava, Alok, Savita Rangarajan, Kaan Kavaklı, et al.. (2021). Fitusiran, an Investigational siRNA Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: First Results from a Phase 3 Study to Evaluate Efficacy and Safety in People with Hemophilia a or B without Inhibitors (ATLAS-A/B). Blood. 138(Supplement 2). LBA–3. 12 indexed citations

11.

Skinner, Mark W., Claude Négrier, Ido Paz‐Priel, et al.. (2021). The effect of emicizumab prophylaxis on long‐term, self‐reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies. Haemophilia. 27(5). 854–865. 34 indexed citations

12.

Kaczmarek, Radosław, Magdy El Ekiaby, Daniel P. Hart, et al.. (2021). Vaccination against COVID‐19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disorders. Haemophilia. 27(4). 515–518. 6 indexed citations

13.

Nissen, Francis, et al.. (2021). Estimating the risk of thrombotic events in people with congenital hemophilia A using US claims data. Journal of Comparative Effectiveness Research. 10(18). 1323–1336. 7 indexed citations

14.

Pipe, Steven W., et al.. (2020). First-in-Human Gene Therapy Study of AAVhu37 Capsid Vector Technology in Severe Hemophilia A - BAY 2599023 has Broad Patient Eligibility and Stable and Sustained Long-Term Expression of FVIII. Blood. 136(Supplement 1). 44–45. 12 indexed citations

15.

Pipe, Steven W., John Pasi, Toshko Lissitchkov, et al.. (2020). Long-Term Durability, Safety and Efficacy of Fitusiran Prophylaxis in People with Hemophilia a or B, with or without Inhibitors - Results from the Phase II Study. Blood. 136(Supplement 1). 3–4. 7 indexed citations

16.

Callaghan, Michael U., Claude Négrier, Ido Paz‐Priel, et al.. (2020). Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Blood. 137(16). 2231–2242. 170 indexed citations

17.

Pipe, Steven W., Radosław Kaczmarek, Alok Srivastava, et al.. (2020). Management of COVID‐19‐associated coagulopathy in persons with haemophilia. Haemophilia. 27(1). 41–48. 9 indexed citations

18.

Konkle, Barbara A., Donna Coffin, Lindsey A. George, et al.. (2020). Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis. 18(11). 3074–3077. 35 indexed citations

19.

Callaghan, Michael U., Claude Négrier, Ido Paz‐Priel, et al.. (2020). Safety and Efficacy of Emicizumab in Persons with Hemophilia a with or without FVIII Inhibitors: Pooled Data from Four Phase III Studies (HAVEN 1-4). Blood. 136(Supplement 1). 3–5. 4 indexed citations

20.

Kaufman, Randal J., Steven W. Pipe, Luigina Tagliavacca, Manju Swaroop, & Micheline J. Moussalli. (1997). Biosynthesis, assembly and secretion of coagulation factor VIII.. PubMed. 8 Suppl 2(1). S3–14. 70 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact